Biopharmaceutical News and Research

RSS

UC Berkeley Extension offers new options for career development in biotechnology

Biotechnology professionals in the Bay Area have three new options for career development from UC Berkeley Extension. The professional programs in Regulatory Affairs, Biopharmaceutical Product and Process Development, and Bioscience Manufacturing and Supply Chain join the education leader's lineup of programs and certificates designed to meet the biotechnology industry's demand for trained professionals.

30 Sep 2010

Senesco fiscal 2010 revenue decreases to $140,000

Senesco Technologies, Inc. reported financial results for the 12 months ended June 30, 2010 ("Fiscal 2010").

29 Sep 2010

HUYA, Quintiles announce agreement to develop HBI-8000 cancer drug

HUYA Bioscience International, the leader in U.S.-China pharmaceutical co-development, and Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced an agreement to co-develop a new cancer drug, HBI-8000, sourced in China by HUYA.

29 Sep 2010

ADLS receives $1.5M from exercise of unit warrants

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced it has received $1.5 million of proceeds from the exercise of the unit warrants issued in the public offering of securities announced on July 1, 2010.

29 Sep 2010

Onconova Therapeutics to present Ex-RAD radioprotectant data at RRS Annual Meeting

Onconova Therapeutics, Inc. is presenting new data in five posters and an oral presentation this week summarizing several studies with the company's radioprotectant Ex-RAD- at the 56th Annual Meeting of the Radiation Research Society (RRS), September 25-29 in Maui, Hawaii.

28 Sep 2010

MediciNova receives FDA approval to proceed with initial trial of ibudilast

MediciNova Inc, a biopharmaceutical company publicly traded on the NASDAQ Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today reported FDA's approval to proceed with an initial trial of the company's neurological drug candidate, ibudilast (MN-166/AV411), as a potential new pharmacotherapy for methamphetamine addiction.

27 Sep 2010

PAREXEL Consulting releases two new white papers on biosimilar development

PAREXEL Consulting, a business unit of PAREXEL International and leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released two new white papers from leading biosimilar experts that provide key insights into emerging areas of biosimilar development.

From Parexel 24 Sep 2010

NeoStem signs merger agreement to acquire Progenitor Cell Therapy

NeoStem, Inc. an international biopharmaceutical company with operations in the U.S. and China and Progenitor Cell Therapy, LLC a privately held cell therapy company that serves the cell therapy industry from licensed, state-of-the art cell therapy manufacturing facilities in New Jersey and California today jointly announced the signing of a definitive merger agreement whereby NeoStem will acquire Progenitor Cell Therapy.

24 Sep 2010

Zalicus presents synergistic drug data at Targeted Cancer Therapies World Europe 2010 meeting

Zalicus Inc. presented data today on its discovery of novel synergistic drug combinations for the treatment of cancer at the Targeted Cancer Therapies World Europe 2010 meeting in Zurich on September 23, 2010.

24 Sep 2010

Tolerx presents otelixizumab preclinical research at 46th EASD

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.

23 Sep 2010

Scarab Genomics, Lonza enter sales agreement for Clean Genome technology

Scarab Genomics, a pioneer in the world of E. coli genomics and production strains, and Lonza, a world leader in biopharmaceutical development and production, announced today the companies have entered into a preferred marketing and sales agreement for Scarab Genomics' Clean Genome E. coli. Financial details of the contract were not disclosed.

23 Sep 2010

NeoStem to present VSEL Technology for Battlefield Wounds treatment at USU-HJF Symposium

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.

23 Sep 2010

BARDA awards Rapid Micro Biosystems $6.7M contract to develop rapid sterility testing platform for vaccines

Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, today announced that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of rapid sterility testing for vaccines as part of the Innovative Platform Technologies program of BARDA's Strategic Science and Technology Division.

23 Sep 2010

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.

22 Sep 2010

Delphi Genetics licences StabyExpress technology for production of protein vaccines to GSK

Delphi Genetics SA has announced today the signature of a licensing agreement with GlaxoSmithKline for the use of the patented StabyExpress technology for the production of protein vaccines for human use.

22 Sep 2010

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Dutch biopharmaceutical company Crucell N.V. and the Aeras Global TB Vaccine Foundation today announced the start of a Phase II clinical trial in infants of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35.

22 Sep 2010

Sinobiopharma fiscal 2010 total revenue increases 101% YoY to $7.7 million

Sinobiopharma, Inc., a fully integrated and highly innovative specialty pharmaceutical company engaged in the research, development, manufacture, and marketing of biopharmaceutical products in China, announced financial results for the fiscal year ended May 31, 2010.

22 Sep 2010

Access enters $30M supply agreement for MuGard with RHEI

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.

21 Sep 2010

immatics raises EUR53.8million in Series C financing round

immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that it has raised EUR53.8million in a Series C financing round. The new funds will allow the Company to finance the ongoing development of immatics' existing pipeline of advanced therapeutic cancer vaccine candidates.

21 Sep 2010

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non-Responders (INR) after at least 24 months of highly active anti-retroviral therapy (HAART).

21 Sep 2010

Biopharmaceutical News and Research

UC Berkeley Extension offers new options for career development in biotechnology

Senesco fiscal 2010 revenue decreases to $140,000

HUYA, Quintiles announce agreement to develop HBI-8000 cancer drug

ADLS receives $1.5M from exercise of unit warrants

Onconova Therapeutics to present Ex-RAD radioprotectant data at RRS Annual Meeting

MediciNova receives FDA approval to proceed with initial trial of ibudilast

PAREXEL Consulting releases two new white papers on biosimilar development

NeoStem signs merger agreement to acquire Progenitor Cell Therapy

Zalicus presents synergistic drug data at Targeted Cancer Therapies World Europe 2010 meeting

Tolerx presents otelixizumab preclinical research at 46th EASD

Scarab Genomics, Lonza enter sales agreement for Clean Genome technology

NeoStem to present VSEL Technology for Battlefield Wounds treatment at USU-HJF Symposium

BARDA awards Rapid Micro Biosystems $6.7M contract to develop rapid sterility testing platform for vaccines

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Delphi Genetics licences StabyExpress technology for production of protein vaccines to GSK

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Sinobiopharma fiscal 2010 total revenue increases 101% YoY to $7.7 million

Access enters $30M supply agreement for MuGard with RHEI

immatics raises EUR53.8million in Series C financing round

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Event guide: World ADC Asia eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News